Advertisement

Medical Oncology

, 30:454 | Cite as

Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer

  • Xia Zhang
  • Qiong Wu
  • Lu Gan
  • Guan-Zhen Yu
  • Rui Wang
  • Zi-Shu Wang
  • Jie-Jun Wang
  • Xi Wang
Original Paper

Abstract

Arachidonic acid metabolic pathway has been implicated in the inflammation-associated tumorigenesis of gastrointestinal cancers. As the rate-limiting enzyme of arachidonic acid production, group IVA phospholipase A2 (PLA2G4A) is hypothesized to play a fundamental role in gastric tumorigenesis as well as cyclooxygenase-2 (COX-2). However, little is known about the expression and role of PLA2G4A in gastric cancer, and the association of PLA2G4A with COX-2 remains to be elucidated. In this study, the mRNA expression of PLA2G4A and COX-2 in 60 pairs of fresh gastric tumors and corresponding adjacent non-cancerous mucosa was detected by using real-time quantitative PCR and the immunostaining of the both proteins in paired samples from 866 gastric cancer patients were assessed by using immunohistochemistry method. The clinicopathological and the prognostic relevance of PLA2G4A and COX-2 expression were determined. The results revealed a significantly reduced expression of PLA2G4A in gastric tumors compared to in non-cancerous tissues, as opposite to the increased expression of COX-2. PLA2G4A was significantly associated with tumor size (P = 0.003), tumor grade (P < 0.001), intestinal type (P = 0.003), T classification (P < 0.001), N classification (P < 0.001), and thereby TNM stage (P < 0.001). PLA2G4A and COX-2 expression were both identified as independent prognostic factors in multivariate Cox model analysis (P = 0.024 for PLA2G4A and P < 0.001 for COX-2). Moreover, the reduced PLA2G4A and increased COX-2 expression was both associated with unfavorable survival for patients with gastric cancer. PLA2G4A might serve as a promising target for future therapeutic approaches to gastric cancer combined with COX-2 inhibitors.

Keywords

Gastric cancer Group IVA phospholipase A2 Cyclooxygenase-2 Prognosis 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 30973432 and No. 81000983).

Conflict of interest

None.

References

  1. 1.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep. 2012;32:1–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55:115–22.Google Scholar
  4. 4.
    Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol. 2005;56(Suppl 5):57–73.PubMedGoogle Scholar
  5. 5.
    Boland CR, Luciani MG, Gasche C, Goel A. Infection, inflammation, and gastrointestinal cancer. Gut. 2005;54:1321–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakanishi M, Rosenberg DW. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta. 2006;1761:1335–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006;1761:1246–59.PubMedCrossRefGoogle Scholar
  9. 9.
    Leslie CC. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids. 2004;70:373–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Saukkonen K, Rintahaka J, Sivula A, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS. 2003;111:915–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Thiel A, Mrena J, Ristimäki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev. 2011;30:387–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009;9:390–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Scott KF, Sajinovic M, Hein J, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 2010;92:601–10.PubMedCrossRefGoogle Scholar
  16. 16.
    Linkous A, Yazlovitskaya E. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Cell Microbiol. 2010;12:1369–77.PubMedCrossRefGoogle Scholar
  17. 17.
    Soydan AS, Tavares IA, Weech PK, Temblay NM, Bennett A. High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue. Eur J Cancer. 1996;32A:1781–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Osterström A, Dimberg J, Fransén K, Söderkvist P. Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas. Cancer Lett. 2002;182:175–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Wendum D, Svrcek M, Rigau V, et al. COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol. 2003;16:130–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Panel V, Boëlle PY, Ayala-Sanmartin J, et al. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006;243:255–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem. 1997;272:14501–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Sundarraj S, Kannan S. Immunohistochemical expression of cytosolic phospholipase A2α in non-small cell lung carcinoma. Asian Pac J Cancer Prev. 2010;11:1367–72.PubMedGoogle Scholar
  23. 23.
    Patel MI, Singh J, Niknami M, et al. Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res. 2008;14:8070–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang S, Du Y, Tao J, Wu Y, Chen N. Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec. 2008;70:242–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Meyer AM, Dwyer-Nield LD, Hurteau GJ, et al. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis. 2004;25:1517–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Dong M, Johnson M, Rezaie A, et al. Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res. 2005;11:2265–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Dong M, Guda K, Nambiar PR, et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis. 2003;24:307–15.PubMedCrossRefGoogle Scholar
  28. 28.
    Ilsley JN, Nakanishi M, Flynn C, et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res. 2005;65:2636–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Soydan AS, Gaffen JD, Weech PK, et al. Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. Eur J Cancer. 1997;33:1508–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Lagorce-Pagès C, Paraf F, Wendum D, Martin A, Fléjou JF. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett’s oesophagus. Virchows Arch. 2004;444:426–35.PubMedCrossRefGoogle Scholar
  31. 31.
    Caiazza F, McCarthy NS, Young L, Hill AD, Harvey BJ, Thomas W. Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. Br J Cancer. 2011;104:338–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Yoo YS, Lim SC, Kim KJ. Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer. J Korean Surg Soc. 2011;80:397–403.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Oncology, Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Medical OncologyFirst Affiliated Hospital of Bengbu Medical CollegeBengbuChina

Personalised recommendations